IDRx emerges from stealth with $122M to block cancer’s ‘escape mutations’

A new biotechnology company has raised $122 million and has plans to block certain types of cancer mutations before they even begin.

Previous Cushman & Wakefield executive promoted to president of Americas
Next Restaurant Roundup: Tailor announces opening date, cocktail lounge at Assembly Food Hall, more

No Comment

Leave a reply

Your email address will not be published.